Royalty Pharma (RPRX) EV to EBITDA (2020 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) EV to EBITDA (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Incyte | 25.65 Bn | 21.11 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 258.09 |
| Mar 31, 2026 | 53.42 |
| Dec 31, 2025 | 64.11 |
| Sep 30, 2025 | 53.09 |
| Jun 30, 2025 | 112.11 |
| Mar 31, 2025 | 36.76 |
| Dec 31, 2024 | 48.23 |
| Sep 30, 2024 | 25.93 |
| Jun 30, 2024 | 63.59 |
| Mar 31, 2024 | -279.72 |
| Dec 31, 2023 | 32.38 |
| Sep 30, 2023 | 123.77 |
| Jun 30, 2023 | 79.79 |
| Mar 31, 2023 | 49.62 |
| Dec 31, 2022 | -54.20 |
| Sep 30, 2022 | 141.83 |
| Jun 30, 2022 | 72.62 |
| Mar 31, 2022 | 117.17 |
| Dec 31, 2021 | 173.03 |
| Sep 30, 2021 | 80.81 |